Impact of GUUD product on glucose variations and metabolic changes in diabetic and non diabetic population.

Impact of GUUD test Product on Glycemic variability and Metabolic Health compared to normal sugar (Sucrose) in obese diabetic and non diabetic patients; A randomized open label two arm two phase crossover design Study – GUUD Health Study. - NA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069256

Enrollment

Registered

2024-06-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: GUUD: GUUD is a novel product manufactured with sugar and stevia combination, it is 50% lower in calories when used as directed. GUUD as sugar crystal provides the same sweetness with h

Eligibility

Inclusion criteria

Inclusion criteria: 1. Overweight/obese patients with or without diabetes (BMI= 25 kg/m2) between ages 18-65 years. 2. Participants who are willing to provide written informed consent. 3. Participant who are willing to follow suggested dietary intervention, and other prescribed guidelines.

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 diabetes. 2. Type2diabetic with severe complication like; heart failure(grade 3-4), CKD etc 3. Patients with advanced renal, hepatic or cardiac disease, cancer. 4. Patients with genetic predisposition to metabolic disorders. 5. Any history of hypersensitivity with stevia glycoside and other components in the test products or an adverse reaction that might affect the study. 6. Women who are pregnant or lactating. 7. Refusal to sign an informed consent.

Design outcomes

Primary

Measure	Time frame
To assess effectiveness of “GUUD test product ? compared to quantity match normal sugar in improving glycemic variability and metabolic function in overweight/obese diabetic and nondiabetic subjects by assessing biochemical investigations.Timepoint: 6 months	—

Secondary

Measure	Time frame
Secondary outcomes shall be reported by analyzing changes in BMI, waist circumference, hip circumference and cardiovascular risk.Timepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Sailesh Lodha

Eternal Heart Care Centre and Research Institute

saileshlodha@gmail.com911415174000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026